Oppenheimer: Buy Five Prime Therapeutics, It's Worth $45/Share
May 15, 2015 at 10:50 AM EDT
In a report published Friday, Oppenheimer analysts initiated coverage on Five Prime Therapeutics Inc (NASDAQ: FPRX) with an Outperform ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.